Neuronetics reports third-quarter 2026 growth, improved profitability, TMS expansion plans, and a broader interventional mental health offering

Neuronetics reported stronger third-quarter 2026 results, with total revenue rising 12.5% year over year to $42.0 million, driven primarily by 20.1% growth in Greenbrook clinic revenue to $26.2 million. Gross margin improved to 52.2%, operating expenses fell 13% to $21.3 million, operating income reached $0.5 million, and adjusted EBITDA improved to $1.9 million from a $4.7 million loss a year earlier. Net loss declined to $1.6 million, while cash from operating and investing activities was $0.8 million. Operational developments included an FDA 510(k) submission for accelerated TMS, a distribution agreement with Wave Neuro to pursue a PTSD indication using EEG-enabled software pending regulatory clearance, and an integration connecting NeuroStar treatment data with AdvancedMD electronic health records. The company maintained its 2026 revenue outlook of $160 million to $164 million and raised its gross-margin expectations, while continuing to prepare an expanded offering that includes psychedelics. Greenbrook clinics also offer SPRAVATO, or esketamine, for treatment-resistant depression.